Nalaganje...
Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib—an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer
Erlotinib is approved for the treatment of non–small cell lung and pancreatic cancers, and is metabolized by CYP3A4. Inducers and inhibitors of CYP3A enzymes such as ritonavir and efavirenz, respectively, may be used as part of the highly active antiretroviral therapy drugs to treat patients with hu...
Shranjeno v:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
The American Society for Pharmacology and Experimental Therapeutics
2013
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3781374/ https://ncbi.nlm.nih.gov/pubmed/23913028 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/dmd.113.052100 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|